Literature DB >> 8592619

Hypercalcaemia complicating systemic oxalosis in primary hyperoxaluria type 1.

C Toussaint1, L De Pauw, C Tielemans, D Abramowicz.   

Abstract

Persistent hypercalcaemia was observed in two patients with oxalate osteopathy complicating primary hyperoxaluria type 1; four other cases have been reported in the literature. In none of the six patients could hypercalcaemia be ascribed to hyper-parathyroidism secondary to renal failure. It occurred in the absence of aluminum intoxication, and was associated with normal calcitriol. Hypercalcaemia responded to mithramycin in one patient, and to corticosteroid administration in three; corticosteroid withdrawal was followed by recurrence of hypercalcaemia in the three cases. It is suggested that hypercalcaemia results from the osteoclast-stimulating activity of macrophages constituting the granulomata which invade the bone marrow in response to oxalate deposition. Whatever its pathogenesis, a trial of corticosteroid appears warranted for treating hypercalcaemia complicating oxalosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8592619     DOI: 10.1093/ndt/10.supp8.17

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  3 in total

Review 1.  Oxalate crystal deposition disease.

Authors:  Irama Maldonado; Vineet Prasad; Antonio J Reginato
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

2.  Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis.

Authors:  Peggy Perrin; Jérome Olagne; Arnaud Delbello; Stanislas Bataille; Laurent Mesnard; Claire Borni; Bruno Moulin; Sophie Caillard
Journal:  Kidney Int Rep       Date:  2021-11-24

3.  In Reply to "Letter Regarding 'Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis'".

Authors:  Peggy Perrin; Jerome Olagne; Arnaud Delbello; Stanislas Bataille; Laurent Mesnard; Claire Borni; Bruno Moulin; Sophie Caillard
Journal:  Kidney Int Rep       Date:  2022-02-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.